171 related articles for article (PubMed ID: 18317875)
1. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease.
Tamura Y; Kosuga M; Yamashita M; Tomioka S; Sasaki M; Hikita T; Nakajima H; Kojima K; Uchida S
Clin Exp Nephrol; 2008 Aug; 12(4):256-263. PubMed ID: 18317875
[TBL] [Abstract][Full Text] [Related]
2. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
[TBL] [Abstract][Full Text] [Related]
3. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
[TBL] [Abstract][Full Text] [Related]
4. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
Cernes R; Mashavi M; Zimlichman R
Vasc Health Risk Manag; 2011; 7():749-59. PubMed ID: 22241949
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
Mori-Takeyama U; Minatoguchi S; Murata I; Fujiwara H; Ozaki Y; Ohno M; Oda H; Ohashi H
Clin Exp Nephrol; 2008 Feb; 12(1):33-40. PubMed ID: 18175062
[TBL] [Abstract][Full Text] [Related]
6. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
Meredith PA
Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
[TBL] [Abstract][Full Text] [Related]
7. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
[TBL] [Abstract][Full Text] [Related]
8. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
9. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
Omoto K; Tanabe K; Tokumoto T; Shimmura H; Ishida H; Toma H
Transplantation; 2003 Oct; 76(8):1170-4. PubMed ID: 14578748
[TBL] [Abstract][Full Text] [Related]
10. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
[TBL] [Abstract][Full Text] [Related]
11. Candesartan cilexetil in the treatment of chronic heart failure.
Baguet JP; Barone-Rochette G; Neuder Y
Vasc Health Risk Manag; 2009; 5(1):257-64. PubMed ID: 19436650
[TBL] [Abstract][Full Text] [Related]
12. Long-term renoprotective effect of candesartan in renal transplant patients.
Ishii T; Yasuda M; Itami Y; Hayashi T; Uemura H; Nose K; Nishioka T
Transplant Proc; 2012 Apr; 44(3):638-41. PubMed ID: 22483458
[TBL] [Abstract][Full Text] [Related]
13. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
[TBL] [Abstract][Full Text] [Related]
14. Candesartan: widening indications for this angiotensin II receptor blocker?
Mendis B; Page SR
Expert Opin Pharmacother; 2009 Aug; 10(12):1995-2007. PubMed ID: 19563275
[TBL] [Abstract][Full Text] [Related]
15. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of treating prehypertension with an angiotensin-receptor blocker.
Julius S; Nesbitt SD; Egan BM; Weber MA; Michelson EL; Kaciroti N; Black HR; Grimm RH; Messerli FH; Oparil S; Schork MA;
N Engl J Med; 2006 Apr; 354(16):1685-97. PubMed ID: 16537662
[TBL] [Abstract][Full Text] [Related]
17. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
[TBL] [Abstract][Full Text] [Related]
18. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
Hoy SM; Keating GM
Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
[TBL] [Abstract][Full Text] [Related]
19. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL
Clin J Am Soc Nephrol; 2017 Oct; 12(10):1595-1600. PubMed ID: 28923834
[TBL] [Abstract][Full Text] [Related]
20. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Kanno Y; Takenaka T; Nakamura T; Suzuki H
Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]